

INTRODUCING

VIRACOR

**TRAC**<sup>™</sup>

Transplant Rejection Allograft Check

The donor-derived cell-free  
DNA test for evaluating  
renal allograft rejection

# Complete Diagnostics for Kidney Transplant Patients

- Noninvasive solutions to help manage rejection, infection and treatment
- Business Simplicity: Seamless lab integration services & comprehensive test menu
- 30+ years of trusted diagnostics & innovation




Eurofins  
Clinical Diagnostics



# VIRACOR TRAC™

An alternative to biopsies, Viracor TRAC utilizes a liquid biopsy to evaluate the percentage of dd-cfDNA in transplant recipient plasma post-transplant, helping to aid physicians in their treatment plan.



## VIRACOR'S TRANSPLANT DIAGNOSTICS PORTFOLIO

	Viracor	CareDx	Natera
Acute Rejection dd-cf DNA	TRAC Kidney	✓	✓
Subclinical Rejection	TruGraf <i>Powered by Transplant Genomics</i>	✗	✗
Infectious Disease Portfolio	BKV, CMV, Fungals, ImmuKnow & more	✗	✗
Therapeutic Drug Monitoring	<b>Immunosuppression:</b> Tacrolimus, Cyclosporine, Everolimus, Sirolimus <b>Antifungals:</b> Voriconazole, Itraconazole, Posaconazole, Isavuconazole	✗	✗

Sensitivity, specificity and positive and negative predictive values of TRAC are comparable in results to those of other dd-cfDNA assays on the market.\*

Working with the American Medical Association/CPT®, Viracor Eurofins has secured a Proprietary Laboratory Analyses (PLA) code for Viracor TRAC™.

VISIT US ONLINE:  
[viracor-eurofins.com/trac](http://viracor-eurofins.com/trac)

\*Data is available on file



Eurofins  
Clinical Diagnostics

MM 1066 REV0 0120

